Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 13Thoracic 2Head & Neck 2Tumor-Agnostic 1Other solid neoplasm 1Myeloid 1Gynecologic 1CNS 1Breast 1

Conditions

Thyroid Neoplasms 1Lung Neoplasms 1Histiocytosis 1Colorectal Neoplasms 1Carcinoma, Non-Small-Cell Lung 1Brain Neoplasms 1

Interventions

fludarabine 30Specimen Handling 28Cyclophosphamide 27Azacitidine 23venetoclax 22fludarabine phosphate 22Biopsy 22ruxolitinib 18Whole-Body Irradiation 17Cytarabine 17Mycophenolic Acid 16Busulfan 16asciminib 15Tacrolimus 15Melphalan 14Injections 12Decitabine 12decitabine and cedazuridine drug combination 11X-Rays 11Magnetic Resonance Spectroscopy 11Stem Cell Transplantation 10Granulocyte Colony-Stimulating Factor 10Sirolimus 9Peripheral Blood Stem Cell Transplantation 9Cyclosporine 9Thiotepa 8Filgrastim 8nilotinib 7Imatinib Mesylate 7Phantoms, Imaging 6

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Panitumumab × Myeloid × 90 days × Clear all
NCT05786924 2026-04-21

Phase 1/2 Trial of S241656 in Selected RAS/MAPK Mutation- Positive Malignancies

Servier

Phase 1/2 Recruiting
554 enrolled
CNSGastrointestinalHead & NeckMyeloidThoracic

Brain Neoplasms, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Thyroid Neoplasms, Colorectal Neoplasms, Histiocytosis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡